Cargando…
Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
Background: Membranous Nephropathy (MN) is a rare autoimmune disease related to PLA2R1 antibodies in 70% of cases. One third of patients enter in spontaneous remission. PLA2R1 epitopes in MN have been characterized in four different domains of PLA2R1 and a mechanism of epitope spreading from the imm...
Autores principales: | Brglez, Vesna, Boyer-Suavet, Sonia, Zorzi, Kévin, Fernandez, Céline, Fontas, Eric, Esnault, Vincent, Seitz-Polski, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438577/ https://www.ncbi.nlm.nih.gov/pubmed/32903623 http://dx.doi.org/10.3389/fmed.2020.00412 |
Ejemplares similares
-
Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021) -
Complement Pathways in Membranous Nephropathy: Complex and Multifactorial
por: Brglez, Vesna, et al.
Publicado: (2020) -
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021) -
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022) -
Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses
por: Cremoni, Marion, et al.
Publicado: (2020)